Tariffs, 100% US tariffs on drugs slip. Trump attacks China: hurts our soya farmers

On the morning of 1 October on the Zurich stock exchange, the agreement did well for the shares of Big Pharma: Roche, Novartis and Lonza (also positive today).

The agreement signed by Pfizer - the specific terms of which remain confidential - is intended to meet the four demands that the White House tenant had made of 17 major pharmaceutical companies in the summer, setting a deadline of the end of September, otherwise high tariffs would be applied.

Pfizer has:
1) voluntarily agreed to implement measures to ensure that Americans receive drug prices that are comparable to those in other developed countries;
2) that prices of newly launched drugs are on par with those in other key markets;
3) Pfizer will also participate in the TrumpRx.gov, which will allow US patients to purchase drugs at a significant discount;
4) most of the company's primary care therapies and a selection of specialty brands will be offered at average discounts of 50 per cent, which can go up to 85 per cent.

"We will make deals with everyone, they are on the waiting list," Trump assured.

We are proud to join President Trump at the White House in celebrating this historic agreement that represents a victory for American patients, for American leadership and for Pfizer," said Albert Bourla, chairman and CEO of the group, who was present at the announcement of the deal. "By working closely with the US administration," he added, "we are reducing costs for patients and boosting investment in the US biopharmaceutical ecosystem, ending the days of American families shouldering the global burden of financing innovation on their own. This is about putting all patients first and ensuring that America remains the world's primary driver of medical innovation." "We now have the certainty and stability we need on two critical fronts, tariffs and pricing, which have reduced industry valuations to historic lows," the Ad continued, noting that he had "agreed to a 3-year grace period during which Pfizer products subject to a Section 232 investigation will not be subject to tariffs, provided we continue to invest in manufacturing in the United States. We have also adopted a balanced global pricing approach that continues to recognise the value of innovation, while ensuring that prices in the US and other developed countries are reasonable and sustainable, maintaining the strength of the US market on par with other developed nations".

"This agreement," Bourla continued, "allows us to invest even more boldly in the United States, fuelling growth, creating jobs and bringing manufacturing back home. Our US workforce of 31,000 employees, supported by 13 manufacturing and distribution sites and 7 major research and development centres, underlines Pfizer's vital role in building a stronger US economy. We are committed to unprecedented resources with an additional $70 billion dedicated to research, development and investment projects in the US over the next few years". An effort that 'comes on top of our investment of more than $83 billion in US biotech innovation from 2018 to 2024, demonstrating how we are strengthening our commitment at this pivotal time, shaping the future of medicine through the pursuit of pioneering innovations and ensuring that the US remains the global hub of medical progress and life improvement,' the manager reiterated. The agreement is now in place and will allow Pfizer to 'fully focus on delivering next-generation care,' the note said, 'focusing on areas where the company's science, scale and agility can make the most meaningful difference for patients, in areas such as oncology, obesity, vaccines, inflammation and immunology.

"Our country's soybean farmers are hurt because China, just for 'negotiating' reasons, won't buy." This was stated in a post on Truth Donald Trump, claiming that "we have made so much money from tariffs that we will take a small portion of it and help our farmers. I WILL NEVER LET OUR FARMERS DOWN!" The "sleepy" Joe Biden "didn't enforce our deal with China, which would buy billions of dollars of our agricultural products, but particularly soybeans. It will all work out for the best. I LOVE OUR FARMERS AND EVERY FARMER IS EXACTLY THAT!" the US president continued. "I will meet with Chinese President Xi in four weeks and soya will be a major topic of discussion. MAKE SOYBEANS AND OTHER CROPS RETURN TO THE GREAT!" concluded Trump.

The Brazilian President, Luiz Inácio Lula da Silva, is willing to continue trade negotiations with his American counterpart, Donald Trump, even with regard to the tariffs imposed by Washington on green gold products, but with one limitation: Brazilian sovereignty and the decisions of the judiciary (including the sentence imposed on former President Jair Bolsonaro) must not be part of the discussion. This was revealed by Foreign Minister Mauro Vieira during a meeting of the Foreign Affairs Committee of the Chamber of Deputies in Brasilia.